These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19660003)

  • 1. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.
    Jiao Z; Shi XJ; Li ZD; Zhong MK
    Br J Clin Pharmacol; 2009 Jul; 68(1):47-60. PubMed ID: 19660003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients.
    Wang M; Duan BL; Yuan YJ; Su X; Zheng H; Wang FS; Sun H
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):433-41. PubMed ID: 27117038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
    Wang HF; Qiu F; Wu X; Fang J; Crownover P; Korth-Bradley J; Schulman S
    Clin Pharmacol Drug Dev; 2014 May; 3(3):235-41. PubMed ID: 27128614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The first experience with sirolimus (Rapamune) after kidney transplantation in Lithuania].
    Asakiene E; Rainiene T; Dainys B
    Medicina (Kaunas); 2005; 41 Suppl 1():93-100. PubMed ID: 15901984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
    Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
    Kovarik JM; Eisen H; Dorent R; Mancini D; Vigano M; Rouilly M; Hsu CH; Rordorf C
    J Heart Lung Transplant; 2003 Oct; 22(10):1117-25. PubMed ID: 14550821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.
    Zhang XQ; Wang ZW; Fan JW; Li YP; Jiao Z; Gao JW; Peng ZH; Liu GL
    Ther Drug Monit; 2012 Apr; 34(2):126-33. PubMed ID: 22377746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
    Staatz CE; Willis C; Taylor PJ; Tett SE
    Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of digoxin in elderly patients.
    Chen R; Zou SL; Wang ML; Jiang Y; Xue H; Qian CY; Xia ZL
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):115-21. PubMed ID: 23096939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
    Kovarik JM; Hsu CH; McMahon L; Berthier S; Rordorf C
    Clin Pharmacol Ther; 2001 Sep; 70(3):247-54. PubMed ID: 11557912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
    MacDonald A; Scarola J; Burke JT; Zimmerman JJ
    Clin Ther; 2000; 22 Suppl B():B101-121. PubMed ID: 10823378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids.
    Zahir H; Keogh A; Akhlaghi F
    Ther Drug Monit; 2006 Dec; 28(6):818-26. PubMed ID: 17203553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.